Another example of the implication of NPs in promoting response to checkpoint inhibitor therapeutics is reported by Bhatia group; their engineered nanoparticles carrying immunostimulatory oligonucleotides plus anti-CTLA-4 treatment achieved synergistic tumor suppression in several animal models of various cancers [181]. This evidence concerns the gene CTLA4 and cancer.